Current concepts of pain management for cancer patients

Yin, Feng; Wang, Ying Wai; Yeung, Sai Ching Jim

doi:10.1007/s12156-008-0071-3

“…However, the analgesic effect of acute CBZ administration was less than that of morphine. This confirms the results of a previous study that reported the analgesic effect of CBZ in chronic neuropathic pain (12). The inhibition of voltage-gated sodium channels in the brain, inhibitory modulation of pain transmission at central adrenergic a-receptors by gama amino-butyric acid, and activation of peripheral adrenergic a-receptors are presumed to participate in the antinociceptive action of CBZ (5).…”

Section: Discussionsupporting

confidence: 91%

Effect of Acute and Chronic Administration of Carbamazepine on Cisplatin-Induced Hyperalgesia in Rats

Nayebi

¹

,

Sharifi

²

,

Ramadzani

³

et al. 2012

Jundishapur J Nat Pharm Prod

8

1

0

View full text Add to dashboard Cite

Article type: Original ArticleBackground: Cisplatin is an effective antineoplastic drug used extensively in the treatment of malignancies. It induces painful peripheral neuropathy at high doses. Objectives:The aim of this study was to investigate the effect of carbamazepine (CBZ) on cisplatin-induced peripheral neuropathic pain by using the tail-flick test. Materials and Methods:The study was performed using male Wistar rats weighing 180-200 g. Neuropathic pain was induced by intraperitoneal (IP) administration of cisplatin (5 mg/kg). The effect of oral (PO) CBZ administration (5, 10, and 15 mg/kg) on cisplatininduced pain was assessed using the tail-flick test. Results: Our results showed that cisplatin (5 mg/kg, IP) induced egregious pain (P < 0.01) on day 15. Acute administration of CBZ (5, 10, and 15 mg/kg, PO) caused significant (P < 0.05) increase in tail-flick time latency in a dose-dependent manner, in comparison with that observed in the control group. Furthermore, chronic administration of CBZ (5, 10, and 15 mg/kg, PO) increased (P < 0.05) the pain threshold on days 5 and 10. The analgesic effect of morphine (5 mg/kg, IP) was greater than that after acute CBZ administration (5, 10, and 15 mg/kg, PO). Conclusions:Our results showed that both acute and chronic CBZ administration attenuated cisplatin-induced pain. We suggest that CBZ can be used clinically for alleviating cisplatin-induced neuropathic pain in cancer patients, without any limitations such as tolerance to analgesic effect.

show abstract

“…However, the analgesic effect of acute CBZ administration was less than that of morphine. This confirms the results of a previous study that reported the analgesic effect of CBZ in chronic neuropathic pain (12). The inhibition of voltage-gated sodium channels in the brain, inhibitory modulation of pain transmission at central adrenergic a-receptors by gama amino-butyric acid, and activation of peripheral adrenergic a-receptors are presumed to participate in the antinociceptive action of CBZ (5).…”

Section: Discussionsupporting

confidence: 92%

Effect of Acute and Chronic Administration of Carbamazepine on Cisplatin-Induced Hyperalgesia in Rats

Nayebi

¹

,

Sharifi

²

,

Ramadzani

³

et al. 2012

Jundishapur J Nat Pharm Prod

View full text Add to dashboard Cite

Article type: Original ArticleBackground: Cisplatin is an effective antineoplastic drug used extensively in the treatment of malignancies. It induces painful peripheral neuropathy at high doses. Objectives:The aim of this study was to investigate the effect of carbamazepine (CBZ) on cisplatin-induced peripheral neuropathic pain by using the tail-flick test. Materials and Methods:The study was performed using male Wistar rats weighing 180-200 g. Neuropathic pain was induced by intraperitoneal (IP) administration of cisplatin (5 mg/kg). The effect of oral (PO) CBZ administration (5, 10, and 15 mg/kg) on cisplatininduced pain was assessed using the tail-flick test. Results: Our results showed that cisplatin (5 mg/kg, IP) induced egregious pain (P < 0.01) on day 15. Acute administration of CBZ (5, 10, and 15 mg/kg, PO) caused significant (P < 0.05) increase in tail-flick time latency in a dose-dependent manner, in comparison with that observed in the control group. Furthermore, chronic administration of CBZ (5, 10, and 15 mg/kg, PO) increased (P < 0.05) the pain threshold on days 5 and 10. The analgesic effect of morphine (5 mg/kg, IP) was greater than that after acute CBZ administration (5, 10, and 15 mg/kg, PO). Conclusions:Our results showed that both acute and chronic CBZ administration attenuated cisplatin-induced pain. We suggest that CBZ can be used clinically for alleviating cisplatin-induced neuropathic pain in cancer patients, without any limitations such as tolerance to analgesic effect.

show abstract

“…Such flexibility though must not obscure that prescribers must be cognisant of ongoing changes in analgesic management and prescribing options. 11,12,24 It is important for physicians and those responsible for clinical governance to know that, given the possibility for idiosyncratic prescribing, they are working within the boundaries of acceptable practice set by their colleagues.…”

Section: Introductionmentioning

confidence: 99%